Trial Profile
Pevonedistat as a Single Agent and in Combination With Chemotherapy in Patients With Malignant Mesothelioma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Pevonedistat (Primary) ; Cisplatin; Pemetrexed
- Indications Malignant-mesothelioma
- Focus Adverse reactions; Therapeutic Use
- 01 Mar 2024 Status changed from completed to discontinued.
- 05 Jun 2023 Status changed from active, no longer recruiting to completed.
- 10 Sep 2021 Planned End Date changed from 1 Oct 2022 to 1 Oct 2023.